Retina Ven Dal Tıkanıklığına Bağlı Makula Ödeminde İntravitreal Bevacizumab (Avastin) Enjeksiyonunun Uzun Dönem Sonuçları

Küsbeci, Tuncay; Inan, Ümit Übeyt; Yavas, Güliz; Inan, Sibel; Tümer, Erhan; Ermis, Sitki Samet
June 2009
Retina-Vitreus/Journal of Retina-Vitreous;Jun2009, Vol. 17 Issue 2, p89
Academic Journal
Purpose: To evaluate the long-term effects of intravitreal bevacizumab injection in patients with macular edema secondary to branch retinal vein occlusion. Materials and Methods: In this retrospective interventional case series, 20 eyes of 20 patients with macular edema secondary to branch retinal vein occlusion for 6 months or more were treated with intravitreal bevacizumab (1.25 mg/0.05 mL). Standardized ophthalmic evaluation, best corrected visual acuity (BCVA) measurement with ETDRS chart, and fundus fluorescein angiography (FFA) were performed at baseline, at 1 month and 3 months, and at 3-month intervals thereafter. Intravitreal bevacizumab injection was repeated in recurring macular edema. The follow-up period was 18 months. Results: No ocular toxicity or adverse effects were observed. The mean number of injections per patient was 2.35±0.9. At baseline mean BCVA was logMAR 1.18±0.7 and improved to 0.62±0.5 after 1 month (p=0.002), 0.61±0.5 at 3 months (p=0.001), 0.66±0.5 at 6 months (p=0.003), 0.67±0.5 at 12 months (p=0.003), and 0.57±0.4 (p=0.006) at 18 months. In 13 eyes, VA increased 2 or more lines. FFA showed a complete or partial decrease in macular edema in all eyes after baseline injections and the same favorable response was obtained after re-injections in cases of recurrences. Conclusion: Intravitreal injection of bevacizumab appears to result in a significant improvement in visual acuity and angiographic findings in patients with macular edema secondary to branch retinal vein occlusion during a followup of 18 months.


Related Articles

  • Bevacizumab: as effective as ranibizumab for AMD, but safe?  // Reactions Weekly;6/2/2012, Issue 1404, p5 

    The article discusses two studies which investigated the effectiveness of ranibizumab (Lucentis) and bevacizumab (Avastin) in treating neovascular age-related macular degeneration (AMD). Researchers have found that the proportion of patients who experienced systemic serious adverse event was...

  • Bevacizumab.  // Reactions Weekly;5/31/2008, Issue 1204, p9 

    The article describes the case of an 88-year-old woman who developed acute endophthalmitis after receiving intravitreal injection of bevacizumab for neovascular age-related macular degeneration. Particular focus is given to her dosing regimen. She experienced decreased vision and increased...

  • Intravitreal triamcinolone acetonide vs bevacizumab for treatment of macular oedema secondary to branch retinal vein occlusion. Cheng, K.-C.; Wu, W.-C.; Chen, K.-J. // Eye;Nov2009, Vol. 23 Issue 11, p2023 

    PurposeTo compare the short-term visual and morphological results of intravitreal triamcinolone acetonide vsintravitreal bevacizumab for eyes with macular oedema secondary to branch retinal vein occlusion (BRVO).DesignRetrospective interventional consecutive case series.MethodsWe reviewed the...

  • Ranibizumab.  // Reactions Weekly;5/5/2007, Issue 1150, p19 

    The article describes case reports of two patients with age-related macular degeneration and choroidal neovascularisation who developed a retinal pigment epithelial (RPE) tear after receiving ranibizumab. The first patient, a 74-year-old man, presented with left eye metamorphopsia, pigment...

  • Bevacizumab less costly, just as safe as ranibizumab in AMD.  // PharmacoEconomics & Outcomes News;Sep2014, Vol. 712 Issue 1, p9 

    The article reports on the findings of a study showing that bevacizumab causes no more side effects than the far more expensive ranibizumab when used to treat agerelated macular degeneration (AMD).

  • IVAN, CATT meta-analysis increases power of results. Mullin, David W.; Nale, Patricia // Primary Care Optometry News;Jul2012, Vol. 17 Issue 7, p9 

    The article reports on the claim by Doctor Usha Chakravarthy that researchers have proven that there is no difference in the use of bevacizumab or ranibizumab in treating neovascular age-related macular degeneration with regard to visual acuity based on a meta-analysis.

  • Triamcinolone.  // Reactions Weekly;10/13/2007, Issue 1173, p26 

    The article describes the case of several patients who developed sterile endophthalmitis following intravitreal injection of triamcinolone. The patients received an intravitreal injection of triamcinolone for cystoid macular oedema. The symptoms associated with sterile endophthalmitis are...

  • The effect of intravitreal bevacizumab and ranibizumab on macular edema of the contralateral eye: A comparative study of two anti-VEGFs. Bakbak, Berker; Ozturk, Banu Turgut; Gonul, Saban; Gedik, Sansal // Oman Journal of Ophthalmology;Feb2016, Vol. 9 Issue 1, p44 

    Purpose: To compare the effects of bevacizumab and ranibizumab on the visual function and macular thickness in the contralateral (untreated) eye of patients with bilateral diabetic macular edema (DME). Materials and Methods: Thirty-nine patients with bilateral DME, who had been treated with both...

  • YaÅŸa BaÄŸlı Makula Dejeneresansında Fotodinamik Tedavi ile Kombine Ä°ntravitreal Pegaptanib.  // Retina-Vitreus/Journal of Retina-Vitreous;Sep2010, Vol. 18 Issue 3, p225 

    No abstract available.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics